3D medical background with male head with brain and DNA strands

The Role of Emerging Therapeutics to Reduce Impairment and Improve Quality of Life for Patients With Early Alzheimer’s Disease


Course Information

Therapautic Area: Neurology
Format(s): Webcast
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: August 28, 2017 to August 27, 2018


Program Overview

This CME program will highlight content presented at the Alzheimer’s Association International Conference 2017 held in London, England. The expert faculty panel will provide an interactive update of recent advances in the treatment and management of patients with Alzheimer’s disease (AD). Pathophysiology, including disease course and prevention strategies, will be discussed. Clinical trial data, particularly regarding emerging therapeutics, will be assessed, considering the potential impact on clinical practice. The three faculty will review techniques for creating tailored treatment plans for patients with Alzheimer’s disease. Following the completion of this activity, learners will have a better understanding of best practices for improving outcomes and quality of life in their AD patients.

Target Audience

Neurologists, primary care physicians, nurse practitioners, nurses and other healthcare professionals who care for patients with Alzheimer’s disease.

Learning Objectives

  1. Discuss the pathophysiology of Alzheimer’s disease, including disease course, signs and symptoms
  2. Analyze clinical trial data for emerging therapeutics for the treatment of Alzheimer’s disease as presented at AAIC 2017
  3. Develop optimal strategies to create patient-specific treatment plans for the healthcare team to improve outcomes and the overall quality of life for patients with Alzheimer’s disease


Rovner Head ShotBarry W. Rovner, MD
Professor, Departments of Neurology, Psychiatry, and Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Jefferson Hospital for Neuroscience
Philadelphia, Pennsylvania 


Isaacson Head ShotRichard S. Isaacson, MD
Associate Professor of Neurology
Weill Cornell Medicine
Director, Alzheimer’s Prevention Clinic
New York Presbyterian Hospital
New York, New York


Schneider Head ShotJulie A. Schneider, MD, MS
Deborah R. and Edgar D. Jannotta Presidential Professor of Pathology and Neurological Sciences
Rush University
Associate Director, Rush Alzheimer’s Disease Center
Rush University Medical Center
Chicago, Illinois


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Barry W. Rovner, MD Nothing to disclose.
Richard S. Isaacson, MD Consultant/Advisor: Eli Lilly and Company; Neurotrack Technologies; 23 and Me
Julie A. Schneider, MD, MS  Consultant/Advisor: Eli Lilly and Company; Genentech, Inc.

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Biogen.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.


Provided by AcademicCME-web